Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Erythromycin on CHF6001 PK in Healthy Subjects
NCT06395610Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tanimilast in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration at 96 hours and Maximum Observed Plasma Concentration at 96 hours. Started Mar 2024; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06395610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395610.